News & Updates

Show Multimedia Only

Lower rates of relapse and discontinuation with ocrelizumab after natalizumab vs dimethyl fumarate and fingolimod in MS

07 Jun 2023 by

A retrospective observational cohort study finds that patients with relapsing-remitting multiple sclerosis (RRMS) who switched from natalizumab to ocrelizumab had lower annual relapse and discontinuation rates and longer time to first relapse than those who switched to dimethyl fumarate or fingolimod.

Lower rates of relapse and discontinuation with ocrelizumab after natalizumab vs dimethyl fumarate and fingolimod in MS

07 Jun 2023

Organ sparing may predispose genitourinary rhabdomyosarcoma patients to extra surgery

06 Jun 2023

Patients with genitourinary rhabdomyosarcoma who undergo organ-sparing treatment have higher odds of additional reconstructive surgery due to compromised urological function, reports a study.

Organ sparing may predispose genitourinary rhabdomyosarcoma patients to extra surgery

06 Jun 2023

Tofacitinib safe, effective in UC, but response fades after dose reduction

06 Jun 2023 by

Treatment with tofacitinib is both safe and effective in a real-world setting, as shown in a Canada study, in which a third of patients with ulcerative colitis (UC) achieved clinical remission with few serious adverse events. However, nearly half of them have lost response following dose de-escalation, and this is only partially recaptured with re-escalation.

Tofacitinib safe, effective in UC, but response fades after dose reduction

06 Jun 2023

Does extended lymph node sampling increase complications?

06 Jun 2023

Patients undergoing more extensive lymph node sampling during surgery for a suspected malignant paediatric renal tumour do not appear to have a higher likelihood of experiencing clinically significant complications, reveals a study.

Does extended lymph node sampling increase complications?

06 Jun 2023

Nivolumab-chemo poised to alter NSCLC treatment landscape

06 Jun 2023 by

In the 3-year analysis of the phase III CheckMate 816 trial, neoadjuvant nivolumab plus platinum doublet chemotherapy (nivo-chemo) continued to provide durable benefit for individuals with resectable non-small-cell lung cancer (NSCLC).

Nivolumab-chemo poised to alter NSCLC treatment landscape

06 Jun 2023

Novel vaginal film for birth control impresses in early-phase trial

06 Jun 2023

Applying a single dose of the novel vaginal film ZB-06 before intercourse is safe and appears to prevent sperm from reaching the egg, according to the results of a phase I, proof-of-concept trial.

Novel vaginal film for birth control impresses in early-phase trial

06 Jun 2023

Adjuvant cisplatin-gemcitabine ups PFS vs cisplatin-fluorouracil in N2–3 NPC after cCRT

06 Jun 2023 by

In Chinese patients with stage N2–3 nasopharyngeal carcinoma (NPC) who have completed concurrent chemoradiotherapy (cCRT), adjuvant cisplatin-gemcitabine significantly improves progression-free survival (PFS) vs current standard of care (SoC) with adjuvant cisplatin-fluorouracil, according to a phase III trial at four cancer centres in China that was reported at ASCO 2023.

Adjuvant cisplatin-gemcitabine ups PFS vs cisplatin-fluorouracil in N2–3 NPC after cCRT

06 Jun 2023

Emergency department–initiated intervention aids secondary prevention of suicide

06 Jun 2023 by

Emergency department (ED)–initiated safety planning intervention (SPI) significantly reduces subsequent suicide behaviours in the 12 months following patients’ initial ED visit, the ED-SAFE 2 trial has shown.

Emergency department–initiated intervention aids secondary prevention of suicide

06 Jun 2023

Benefits of mRNA COVID-19 vaccines for Omicron outweigh risks regardless of age, sex, or comorbidities

06 Jun 2023

The benefits of mRNA vaccines are much larger than the risks, for both the primary series and the booster doses, across all ages, sexes, and the presence or absence of comorbidities, even considering the reduced disease severity of the Omicron variant.

Benefits of mRNA COVID-19 vaccines for Omicron outweigh risks regardless of age, sex, or comorbidities

06 Jun 2023

Camrelizumab plus apatinib and temozolomide delivers in advanced acral melanoma

05 Jun 2023

The combination of camrelizumab plus apatinib and temozolomide appears to be beneficial in the first-line treatment of advanced acral melanoma, with the majority of the patients showing response and an acceptable safety profile, according to the results of a phase II study.

Camrelizumab plus apatinib and temozolomide delivers in advanced acral melanoma

05 Jun 2023

News & Updates

Showing Multidisciplinary articles

Showing

Specialty:

Lower rates of relapse and discontinuation with ocrelizumab after natalizumab vs dimethyl fumarate and fingolimod in MS

Lower rates of relapse and discontinuation with ocrelizumab after natalizumab vs dimethyl fumarate and fingolimod in MS

Organ sparing may predispose genitourinary rhabdomyosarcoma patients to extra surgery

Organ sparing may predispose genitourinary rhabdomyosarcoma patients to extra surgery

Tofacitinib safe, effective in UC, but response fades after dose reduction

Tofacitinib safe, effective in UC, but response fades after dose reduction

Does extended lymph node sampling increase complications?

Does extended lymph node sampling increase complications?

Nivolumab-chemo poised to alter NSCLC treatment landscape

Nivolumab-chemo poised to alter NSCLC treatment landscape

Novel vaginal film for birth control impresses in early-phase trial

Novel vaginal film for birth control impresses in early-phase trial

Adjuvant cisplatin-gemcitabine ups PFS vs cisplatin-fluorouracil in N2–3 NPC after cCRT

Adjuvant cisplatin-gemcitabine ups PFS vs cisplatin-fluorouracil in N2–3 NPC after cCRT

Emergency department–initiated intervention aids secondary prevention of suicide

Emergency department–initiated intervention aids secondary prevention of suicide

Benefits of mRNA COVID-19 vaccines for Omicron outweigh risks regardless of age, sex, or comorbidities

Benefits of mRNA COVID-19 vaccines for Omicron outweigh risks regardless of age, sex, or comorbidities

Camrelizumab plus apatinib and temozolomide delivers in advanced acral melanoma

Camrelizumab plus apatinib and temozolomide delivers in advanced acral melanoma